Professor Zhang Ge (left) and Dr Liang Chao win the First Prize of the Beijing Science and Technology Award for their collaborative research in bone and joint diseases


張戈教授 (左) 與梁超博士的聯合研究項目獲頒北京市科學技術獎一等獎

Date: 12 Apr 2018 (Thursday)

Archive

Two Chinese medicine scholars claim top prize of Beijing Science and Technology Award for collaborative research in bone and joint diseases

中醫藥學院兩學者喜獲北京市科學技術獎一等獎

Professor Zhang Ge, Director of the Technology Development Division, and Associate Director of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases of the School of Chinese Medicine (SCM), and Research Assistant Professor Dr Liang Chao recently won the First Prize of the Beijing Science and Technology Award 2017 for their collaborative research project entitled “Mechanism of post-translational modification in protein homeostasis control”. The project was conducted in collaboration with the Chinese Academy of Military Medical Science and the Chinese PLA General Hospital.
 
The award-winning project took eight years to complete. Their research findings were previously published in premier scientific journal Nature Medicine, first in 2012 under the title of “A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy” and then in 2015 under the title of “Aptamer-functionalised lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy”.
 
During the beginning stages of the project, the joint research team developed a targeting system for delivering osteogenic siRNAs specifically to bone-formation surfaces; the systemic delivery of osteogenic siRNA in osteoporotic rats using this system resulted in the selective enrichment of the siRNAs in osteogenic cells and enhanced bone formation and bone mass. Later, the team further developed an osteoblast-specific aptamer-functionalised delivery system and advanced the targeted delivery selectivity of osteogenic siRNAs from the tissue level to the cellular level. Such an approach has significantly promoted bone formation and enhanced bone mass in osteoporotic rats. The overall research findings have advanced the translational application of the RNAi-based bone anabolic strategy. 

中醫藥學院技術開發部主任兼羅守輝骨與關節疾病轉化醫學研究所副所長張戈教授、研究助理教授梁超博士與中國人民解放軍軍事醫學科學院放射與輻射醫學研究所和解放軍總醫院聯合進行的「蛋白質穩態調控的翻譯後修飾機制」研究項目,最近榮獲2017年北京市科學技術獎一等獎。
 
得獎的研究項目歷時近八年,研究結果先後於2012和2015年在國際著名科學雜誌《自然─醫學》上發表,題為「靶向骨形成表面的遞送系統有助於實現RNA干擾為基礎的成骨治療策略」和「靶向成骨細胞的適配子功能化的脂質納米顆粒可用於RNA干擾為基礎的成骨治療策略」。
 
在第一部分的研究中,聯合研究團隊開發了可以靶向成骨小干擾核酸至骨形成表面的遞送系統,並將該系統應用在患骨質疏鬆的大鼠上,從中實現成骨系細胞中小干擾核酸的特異性富集,以及改善骨形成和骨量。研究團隊其後進一步開發了成骨細胞特異性適配子功能化的遞送系統,將現有小干擾核酸成骨遞送系統的選擇性由組織水平提高至細胞水平,更有效地增加患骨質疏鬆大鼠體內的骨量,並促進其骨形成。整項研究成果大大加速了以RNA干擾為基礎的成骨治療策略的臨床轉化應用。